Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 486.5 INR 1.75% Market Closed
Market Cap: 1.2T INR
Have any thoughts about
Cipla Ltd?
Write Note

Cipla Ltd
Equity Earnings Affiliates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipla Ltd
Equity Earnings Affiliates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Equity Earnings Affiliates CAGR 3Y CAGR 5Y CAGR 10Y
Cipla Ltd
NSE:CIPLA
Equity Earnings Affiliates
-â‚ą44.7m
CAGR 3-Years
23%
CAGR 5-Years
37%
CAGR 10-Years
18%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Equity Earnings Affiliates
-â‚ą194.2m
CAGR 3-Years
-4%
CAGR 5-Years
-15%
CAGR 10-Years
-21%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Equity Earnings Affiliates
â‚ą1.2B
CAGR 3-Years
45%
CAGR 5-Years
24%
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cipla Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals

Cipla Ltd. stands as a prominent player in the global pharmaceutical landscape, rooted in its founding vision of accessible healthcare for all. Established in 1935 in India, the company has evolved from its initial focus on producing affordable medicines to becoming a leading provider of generic and specialty pharmaceuticals, over-the-counter products, and active pharmaceutical ingredients (APIs). With a strong commitment to innovation, Cipla allocates a significant portion of its resources to research and development, leading to a robust pipeline of patented and life-saving treatments, particularly in the fields of respiratory, HIV/AIDS, and oncology therapies. This focus on both global markets and local needs has positioned Cipla not only as a trusted brand in India but also as a key player in over 80 countries worldwide. For investors, Cipla represents a compelling opportunity due to its strategic initiatives aimed at sustaining growth amidst challenging market dynamics. The company's impressive financial performance, characterized by steady revenue growth and healthy margins, underscores its operational efficiency and market-leading position. Cipla’s proactive approach to collaborations, licensing agreements, and technological advancements indicates a future that embraces pharmaceutical innovations while maintaining cost-effective solutions. Furthermore, its commitment to sustainability and ethical practices resonates well in today's socially conscious investing landscape. As healthcare demands continue to rise globally, Cipla's mission to enhance access to vital medications stands to benefit both patients and shareholders alike.

CIPLA Intrinsic Value
1 173.46 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Cipla Ltd's Equity Earnings Affiliates?
Equity Earnings Affiliates
-44.7m INR

Based on the financial report for Sep 30, 2024, Cipla Ltd's Equity Earnings Affiliates amounts to -44.7m INR.

What is Cipla Ltd's Equity Earnings Affiliates growth rate?
Equity Earnings Affiliates CAGR 10Y
18%

Over the last year, the Equity Earnings Affiliates growth was -481%. The average annual Equity Earnings Affiliates growth rates for Cipla Ltd have been 23% over the past three years , 37% over the past five years , and 18% over the past ten years .

Back to Top